137 related articles for article (PubMed ID: 10665790)
1. Results of ruthenium irradiation of uveal melanomas: the Dutch experience.
Tjho-Heslinga RE; Davelaar J; Kemme HM; de Vroome H; Oosterhuis JA; Bleeker JC; Leer JW
Radiother Oncol; 1999 Nov; 53(2):133-7. PubMed ID: 10665790
[TBL] [Abstract][Full Text] [Related]
2. Results of ruthenium irradiation of uveal melanoma.
Tjho-Heslinga RE; Kakebeeke-Kemme HM; Davelaar J; de Vroome H; Bleeker JC; Oosterhuis JA; Leer JW
Radiother Oncol; 1993 Oct; 29(1):33-8. PubMed ID: 8295985
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium-106 plaque brachytherapy for uveal melanoma.
Tarmann L; Wackernagel W; Avian A; Mayer C; Schneider M; Winkler P; Langmann G
Br J Ophthalmol; 2015 Dec; 99(12):1644-9. PubMed ID: 25979763
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
5. Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy.
Lee CS; Jun IH; Kim TI; Byeon SH; Koh HJ; Lee SC
Acta Ophthalmol; 2012 Jun; 90(4):e314-20. PubMed ID: 22429778
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
Perri P; Fiorica F; D'Angelo S; Lamberti G; Parmeggiani F; Martini A; Carpenteri F; Colosimo C; Micucci M; Perazzini L; De Gugliemo E; Berretta M; Sebastiani A; Cartei F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717
[TBL] [Abstract][Full Text] [Related]
8. Possible effects of radiobiological parameters on metastatic spread of uveal melanomas treated with 106Ru plaques.
Kleineidam M; Guthoff R
Ger J Ophthalmol; 1994 Jan; 3(1):22-5; discussion 25-6. PubMed ID: 8142877
[TBL] [Abstract][Full Text] [Related]
9. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience.
Seregard S; aft Trampe E; Lax I; Kock E; Lundell G
Acta Ophthalmol Scand; 1997 Feb; 75(1):11-6. PubMed ID: 9088393
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.
Lommatzsch PK; Werschnik C; Schuster E
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):129-37. PubMed ID: 10766281
[TBL] [Abstract][Full Text] [Related]
11. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
12. Does escalation of the apical dose change treatment outcome in beta-radiation of posterior choroidal melanomas with 106Ru plaques?
Hermann RM; Pradier O; Lauritzen K; Ott M; Schmidberger H; Hess CF
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1360-6. PubMed ID: 11955750
[TBL] [Abstract][Full Text] [Related]
13. [Long-term results of cobalt 60 curietherapy for uveal melanoma].
Bacin F; Kwiatkowski F; Dalens H; Rozan R; Gagyi S; Donnarieix D; Bard JJ; Robert JL
J Fr Ophtalmol; 1998 May; 21(5):333-44. PubMed ID: 9759427
[TBL] [Abstract][Full Text] [Related]
14. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
15. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients - the Tuebingen experience.
Süsskind D; Dürr C; Paulsen F; Kaulich T; Bartz-Schmidt KU
Acta Ophthalmol; 2017 Dec; 95(8):e727-e733. PubMed ID: 27914117
[TBL] [Abstract][Full Text] [Related]
16. Visual outcome of eyes with malignant melanoma of the uvea after ruthenium plaque radiotherapy.
Summanen P; Immonen I; Kivelä T; Tommila P; Heikkonen J; Tarkkanen A
Ophthalmic Surg Lasers; 1995; 26(5):449-60. PubMed ID: 8963860
[TBL] [Abstract][Full Text] [Related]
17. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.
Shields CL; Shields JA; Cater J; Gündüz K; Miyamoto C; Micaily B; Brady LW
Arch Ophthalmol; 2000 Sep; 118(9):1219-28. PubMed ID: 10980767
[TBL] [Abstract][Full Text] [Related]
18. [Eye-preserving treatment of uveal melanoma. Leidse Oogmelanoom Groep].
Keunen JE; Bleeker JC
Ned Tijdschr Geneeskd; 1997 Oct; 141(42):2005-9. PubMed ID: 9550751
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
20. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.
Espensen CA; Appelt AL; Fog LS; Thariat J; Gothelf AB; Aznar MC; Kiilgaard JF
Acta Oncol; 2020 Aug; 59(8):918-925. PubMed ID: 32412331
[No Abstract] [Full Text] [Related]
[Next] [New Search]
